Product Candidates
Phase 1 trial of EPI-7386
ESSA is completing a monotherapy Phase 1 open-label clinical trial evaluating masofaniten (formerly EPI-7386), an investigational first-in-class N-terminal domain androgen receptor inhibitor, for the treatment of adult patients with castration-resistant prostate cancer (CRPC) resistant to standard-of-care treatments.
Phase 1/2 trial of EPI-7386
ESSA is conducting a combination Phase 1/2 clinical trial evaluating masofaniten + enzalutamide in mCRPC patients who have not yet been treated with second-generation antiandrogen therapies.

Investigator Videos

Mark Markowski, MD, PhD Associate Professor of Oncology, Johns Hopkins Kimmel Cancer Center in Baltimore, discusses ESSA’s Phase 2 masofaniten (EPI-7386) + enzalutamide clinical trial with UroToday.

Ronald Tutrone, MD, FACS, CPI Director of Research, Chesapeake Urology, discusses ESSA’s Phase 2 masofaniten (EPI-7386) + enzalutamide clinical trial with UroToday.

Andrew Laccetti, MD, MS Medical Oncologist, Memorial Sloan Kettering Cancer Center, discusses ESSA’s Phase 1 masofaniten (EPI-7386) + enzalutamide clinical trial results on OncLive.

Monotherapy Study

Russell Pachynski, MD, Associate Professor of Medicine, Washington University School of Medicine in St. Louis, discusses ESSA’s Phase 1 EPI-7386 monotherapy clinical trial with UroToday at the American Society for Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2023.

Combination Study

Andrew Laccetti, MD, MS, Medical Oncologist, Memorial Sloan Kettering Cancer Center, discusses ESSA’s Phase 1/2 EPI-7386 + enzalutamide combination clinical trial with UroToday at the American Society for Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2023.